Clinical Significance of Tumor Regression Grade in Rectal Cancer with Preoperative Chemoradiotherapy by Park, Young Joo et al.
pISSN 2093-7822   eISSN 2093-7830
www.coloproctol.org
Journal of the Korean Society of
Coloproctology
www.coloproctol.org 279
Clinical Significance of Tumor Regression Grade in  
Rectal Cancer with Preoperative Chemoradiotherapy
Young Joo Park, Byung Ryul Oh, Sang Woo Lim, Jung Wook Huh, Jae Kyun Joo, Young Jin Kim,  
Hyeong Rok Kim
Department of Surgery, Chonnam National University Medical School, Gwangju, Korea
Original Article
J Korean Soc Coloproctol 2010:26(4);279-286
DOI: 10.3393/jksc.2010.26.4.279
Purpose: Neoadjuvant chemoradiotherapy applied to the locally advanced rectal cancer reduces local recurrence and im-
proves survival. We assessed tumor regression grade (TRG) and its influence on survival in rectal cancer patients treated 
with chemoradiotherapy followed by surgical resection. 
Methods: We studied 108 patients that were seen at our hospital between August 2004 and December 2008. Patients re-
ceived preoperative chemoradiotherapy consisting of 5-fluorouracil and leucovorin by continous infusion during the first 
and fifth week, delivered with concurrent pelvic radiation of 50.4 Gy, followed by radical surgery at 6-8 weeks. The TRG 
was determined by the amount of fibrosis in the tumor embedding area and was divided into 5 grades based on the rela-
tive amount of fibrosis. We analyzed all preoperative clinicopathologic factors, postoperative pathologic stages, TRG and 
prognosis, retrospectively.
Results: Downstaging of rectal cancer through neoadjuvant chemoradiotherapy occurred in 64 (59%) patients. The num-
bers of total regressions (TRG4), good regressions (TRG3), moderate regressions (TRG2), minor regressions (TRG1), and 
no regression (TRG0) were 19 (18%), 65 (60%), 17 (16%), 6 (5%), and 1 (1%) respectively. The TRG was inversely correlated 
with perineural invasion and lymphovascular invasion (P = 0.008, P = 0.032). The local recurrence rate declined as the tu-
mor regression grade increased (P = 0.032). The 19 patients with TRG4 had a better three-year disease free survival than 
the 89 patients with TRG0-3 (P = 0.034). The 16 patients with pathologic complete remission (pCR) had a better three-year 
disease free survival than the 92 patients with non-pCR (P = 0.025). 
Conclusion: Higher TRG after preoperative chemoradiotherapy for rectal cancer closely correlates with better survival 
and low local recurrence. The TRG is considered to be a significant prognostic factor.
Keywords: Rectal cancer; Tumor regression grade; Preoperative chemoradiotherapy
surgery accompanied by preoperative radiotherapy [2, 3]. This 
greatly affects the patients’ survival rate, and research to reduce 
the local recurrence and distant metastases is being done. Es-
pecially, preoperative chemoradiotherapy is known to reduce 
the local recurrence, reduce the tumor size [4], stabilize the 
tumor margin to increase resectability, increase the anal sphinc-
ter conservation rate [5], and reduce tumor metastasis by elim-
inating local lymph nodes and blocking metastasis routes [6]. 
The tumor regression grade (TRG) was first introduced by 
Mandard et al. [7] through a patient with esophageal cancer. 
The TRG can categorize cancer cell ratio from tissue with fibro-
sis or inflammation in numerous stages throughout chemora-
diotherapy. In addition, Suarez et al. [8] reported that the TRG 
might be a superior prognostic factor in predicting the survival 
rather than TN downstaging after preoperative chemoradio-
therapy. Berger et al. [9] reported a better disease-free survival 
INTRODUCTION
Rectal cancer is an increasing disease in South Korea and shows 
a local recurrence rate of 15-40% when only surgical treatment 
is executed [1]. In addition, the local recurrence rate of locally 
advanced rectal cancer is reported to be 4-27% after radical 
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rate in a pathologic complete remission (pCR) group. Habr-
Gama et al. [10] reported similar treatment results from a clini-
cally CR group with surgical excision and a clinically CR group 
with only catamnesis observation.
This study measured the TRG for rectal cancer patients who 
underwent surgery after chemoradiotherapy. The study is in-
tended to guide a future treatment plan for rectal cancer pa-
tients by analyzing clinicopathological factors, overall survival 
rate and disease-free survival rate.
METHODS
Object of study
From September 2004 to December 2008, among 142 patients 
who had chemoradiotherapy before surgery at Chonnam Na-
tional University Hwasun Hospital, the 108 patients with the 
exception of patients who did not finish chemoradiotherapy, 
failed to execute radical excision, failed to measure TRG, had 
metastasis at diagnosis, or failed to have follow-up observation 
over 1 year were retrospectively analyzed. Preoperative chemo-
radiotherapy was executed in patients with rectal cancer lo-
cated within 10 cm of the anal verge, and no distant metasta-
sis tumor located near the anal verge in spite of the low stage 
of the disease.
Methods
Radiation therapy was executed either as 2-dimensional or 3- 
dimensional conformal therapy by using high-energy X-rays 
(6 MV or 10 MV). The daily radiation dose was 180 cGy, 5 
times a week, for 5 weeks, for a total of 4,500 cGy, with con-
ventional fractionation encompassing the rectum and intra-
pelvic lymph node. A dose of 540 cGy was added on the pri-
mary area and the high risk area after reducing the boost field, 
projecting a total of 5,040 cGy. Chemotherapy was executed 
by continuously injecting 5-fluorouracil (5-FU) (500 mg/m
2/
day) and leucovorin (20 mg/m
2) during the first and last week 
of radiotherapy. One round of chemotherapy was done in five 
days and two rounds were done in total [11].
Diagnosis, postoperative follow-up test, and pathogenesis
As basic tests before treatment, digital rectal examination, a 
blood test, a serum carcinoembryonic antigen (CEA), simple 
chest X-ray, abdominopelvic CT, pelvic MRI, positron emis-
sion tomography (PET), colonoscopy, and biopsy were exe-
cuted. Tumor shapes were categorized as ‘fungating’ or ‘ulcer-
ative’ based on the findings of colonoscopy. Patients with pol-
ypoid and ulcerofungating tumor were categorized as the 
fungating group, and patients with ulceroinfiltrative tumor 
were categorized as the ulcerative group. Histological catego-
rization was done based on results of colonoscopic biopsy and 
was recorded as well differentiated, moderately differentiated, 
and poorly differentiated. Mucinous differentiation was con-
sidered as poorly differentiated. Also, perineural invasion and 
lymphovascular invasion were measured based on the post-
operative pathologic findings.
Follow-up examination after surgery was done every 3 months 
in the first 2 years and every 6 months after that. Categories of 
examinations were digital rectal examination, laboratory test, 
serum CEA, chest X-ray and abdominopelvic CT. Chest CT, 
pelvic MRI, and PET scans were executed based on need. Patho-
logic stage was done by following the categorization of the 2002 
American Joint Committee on Cancer (AJCC), 6th edition.
Surgical treatment
Surgery was executed 6-8 weeks after chemoradiotherapy had 
been completed. High ligation and total mesorectal excision 
(TME) were set as bases in all patients. Great caution was taken 
during high ligation in order to prevent damaging to the ini-
tial segment of the intra-pelvic sympathetic nervous system. 
A double ligation was executed on the proximal side of the 
inferior mesenteric artery. Following the visceral layer of the 
mesorectal fascia and the avascular layer between parietal lay-
ers, Waldeyer’s fascia was the rear boundary, and Denonvil-
liers’ fascia and peritoneal reflexion were the front boundary 
where dissection was executed. Dissection was done until the 
front and the lateral surfaces cross the rear surface. The pelvic 
nerve was conserved on both lateral surfaces.
Tumor regression grade
Downstaging was done by comparing pathologic stage after 
surgery with clinical stage before chemoradiotherapy. The patho-
logic treatment response was determined by two pathologists 
re-analyzing pathology slides. The 5-stage system suggested by 
Dworak et al. [12] was used, and categorization was based on the 
degree of fibrosis, necrosis, and change in blood vessels (Table 1, 
Table 1. Tumor regression grade (TRG) 
Grade Definition
TRG0 No regression Fibrosis was completely absent
TRG1 Minor regression Dominant tumor mass with obvious fibrosis in 25% or less of the tumor mass
TRG2 Moderate regression Dominant tumor mass with obvious fibrosis in 26% to 50% of the tumor mass
TRG3 Good  regression Dominant fibrosis outgrowing the tumor mass; more than 50% tumor regression
TRG4 Total regression No viable tumor cells; only fibrotic massJournal of the Korean Society of
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Fig. 1) [13]. Pathologic complete remission (pCR) was defined 
as pT0N0, for which the primary site of resected specimen and 
lymph node did not show tumor cells.
Statistical analysis
Statistical analysis was done by using SPSS ver. 15.0 (SPSS Inc., 
Chicago, IL, USA). Frequency difference in each group was 
checked with a Turkey Post-Hoc test after a one-way layout 
analysis and a Pearson χ2 test. The survival rates were compared 
with the Kaplan-Meier method and the log-rank test. When 
the P-value was less than 0.05, the result was considered to have 
statistical significance.
RESULTS
Patient characteristics
The subject group had a total of 108 people: 85 male (79%) 
and 23 female (21%). The average age was 59.7 ± 11.8 (31-80). 
Ninety-six patients (89%) had lower rectal cancer (within 5 cm 
from the anal verge) and 12 patients (11%) had mid-rectal can-
cer (within 10 cm from the anal verge). The histological cate-
gorizations were 43 well differentiated (40%), 57 moderately 
differentiated (53%), and 5 poorly differentiated (5%), and 86 
patients (80%) had a fungating tumor. Clinical stage before 
concurrent chemoradiotherapy (CCRT) was 8 stage I (7%), 33 
stage II (31%), and 67 stage III (62%).
Surgical treatment and complications
Among the 108 patients who had surgery after CCRT execu-
tion, 84 (78%) had laparoscopic surgery, and types of surgery 
are shown in Table 2. One patient who underwent a subtotal 
colectomy also had a tumor in the rectum and descending co-
lon. As a result, the ascending colon was conserved, and the 
patient underwent a subtotal colectomy.
As postoperative complications, there were 4 patients with 
anastomosis leakage (4%) and 5 patients with intra-pelvic ab-
scess (5%). Patients with anastomosis leakage were treated 
with an ileostomy or T-loop colostomy, and patients with an 
D
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Fig. 1. Microscopic appearances of rectal tissue. (A) Tumor regression grade 1: minor re-
gression and fibrosis in only 25% or less of the tumor mass. (B) Tumor regression grade 2: 
moderate regression, and dominant tumor mass with obvious fibrosis in 26% to 50% of the 
tumor mass. (C) Tumor regression grade 3: good regression and dominant fibrosis outgrow-
ing the tumor mass with more than 50% tumor regression. (D) Tumor regression grade 4: 
total regression, no viable tumor cells, and only fibrotic mass (H&E, × 20).
Table 2. Type of surgery after preoperative chemoradiotherapy
Type of surgery No. (%)
Low anterior resection 45 (42)
Abdominoperineal resection 18 (16)
Intersphincteric resection 43 (40)
Hartmann's operation 1 (1)
Subtotal colectomy 1 (1)
Table 3. Tumor regression grade (TRG) with respect to the primary 
tumor in 108 patients treated with preoperative chemoradiotherapy 
and surgery
TRG No. (%)
TRG0 1 (1)
TRG1 6 (5)
TRG2 17 (16)
TRG3 65 (60)
TRG4 19 (18)
Total  108Journal of the Korean Society of
Coloproctology
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intra-pelvic abscess were treated with antibiotics and external 
drainage. No patients died because of the surgical treatment.
Preoperative chemoradiotherapy treatment results
The TRG distribution was 1 TRG0 (1%), 6 TRG1 (5%), 17 
TRG2 (16%), 65 TRG3 (60%) and 19 TRG4 (18%) (Table 3). 
Among the TRG4 patients, 3 showed N (+); one patient among 
the TRG 3 patients showed Tis and was diagnosed as yp0. In 
64 of the 108 patients (59%), final pathologic stages were re-
duced through CCRT. But two patients were diagnosed as stage 
IV. One patient had liver metastasis based on abdominal CT 
after CCRT, went through a left lateral sectionectomy, and was 
Table 4. Comparison between pre-concurrent chemoradiotherapy stage and pathologic stage
Pre-CCRT stage
Postoperative pathologic stage
  yp0   ypI   ypII ypIIIA ypIIIB ypIIIC ypIV Total
I    1
a   7     8
II    5
a    9
a 16   1 2   33
IIIA    2
a    1
a 1     4
IIIB    7
a    5
a  13
a  3
a   8 5   41
IIIC    2
a    1
a    9
a  1
a    5
a 4   22
Total 17 22 39 5 14 9 2 108
CCRT, concurrent chemoradiotherapy.
aDownstaging number.
Table 5. Correlation between tumor regression grade (TRG) and clinicopathologic factors
TRG0&1  TRG2  TRG3  TRG4  P-value
Age (yr) 68.0 ± 7.87 57.88 ± 12.12 59.88 ± 12.33 57.37 ± 11.81 0.203
Sex
   Male
   Female
6 (86)
1 (14)
14 (82)
  3 (18)
 49 (76)
 16 (24)
16 (84)
  3 (16)
0.794
Tumor site
   Middle (> 5, ≥ 10 cm)
   Lower (≤ 5 cm)
1 (14)
6 (86)
               0
  17 (100)
 6 (9)
 59 (91)
  5 (26)
14 (74)
0.073
Histologic type
   Well differentiated 
   Moderately differentiated
   Poorly differentiated
   Unknown
4 (58)
2 (28)
1 (14)
              0
  4 (24)
13 (76)
               0
               0
 28 (43)
 33 (50)
 3 (5)
 1 (2)
  7 (37)
  9 (47)
1 (5)
  2 (11)
0.369
Macroscopic shape
   Ulcerative
   Fungating
1 (14)
6 (86)
  4 (24)
13 (76)
 16 (25)
 49 (75)
1 (5)
18 (95)
0.312
Pre-CCRT CEA (ng/mL) 7.72 10.87 11.7 4.77 0.564
Pre-CCRT stage
   I
   II
   IIIA
   IIIB
   IIIC
              0
1 (14)
              0
3 (43)
3 (43)
  2 (12)
  6 (35)
               0
  8 (47)
1 (6)
 5 (8)
 22 (33)
 2 (3)
 22 (35)
 14 (21)
1 (5)
  4 (21)
  2 (11)
  9 (47)
  3 (16)
0.553
Postoperative N stage
   ypN0
   ypN1
   ypN2
2 (29)
5 (71)
              0
13 (76)
  4 (24)
               0
 49 (74)
   8 (13)
   8 (13)
16 (84)
  2 (11)
1 (5)
0.003
Perineural invasion 4 (58)   7 (41)  22 (33)                0 0.008
Lymphovascular invasion  2 (28)    5 (29)    7 (11)                0 0.032
Values are presented as numbers (%).
CCRT, concurrent chemoradiotherapy; CEA, carcinoembryonic antigen.Journal of the Korean Society of
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diagnosed as ypT2N0M1. The other patient was diagnosed as 
cT3N0 before surgery, but metastasis was found in a lymph 
node biopsy paraaorta during surgery (Table 4).
Group comparison based on TRG
Based on the TRG, age, sex, location of tumor, histological 
differentiation, shape of tumor and CEA before CCRT execu-
tion were analyzed, and no relationship to the TRG was found. 
Clinical stage before CCRT did not have a statistically signifi-
cance relation to the TRG (P = 0.553). Based on the final bi-
opsy results after surgery, the ypN stage was compared be-
tween groups. ypN (+) was reduced as TRG increased (P = 
0.003). Also, perineural invasion and lymphovascular invasion 
decreased as TRG increased (P = 0.008, P = 0.032) (Table 5).
The average postsurgical follow-up observation period was 
27 months. Local recurrence occurred in 16 patients (15%): 3 
patients (43%) had TRG0 & 1, 4 patients (24%) had TRG2, and 
9 patients (14%) had TRG3. Most recurrence were intra-pel-
vic recurrence, and local recurrence decreased as the TRG in-
creased (P = 0.032). Twenty-six patients (24%) had distant me-
tastasis, and 17 of those (65%) had lung metastasis. Lung me-
tastasis was detected in two patients with TRG4 21months 
from the surgery, and 1 out of 2 was N (+) (Table 6).
Overall survivals (OS) for TRG0&1, TRG2, TRG3, and TRG4 
in 3 years were 51%, 66%, 86%, and 94%, respectively. The three-
year disease-free survival (DFS) rates were 48%, 51%, 68%, and 
76%, respectively. The three-year overall survival and the three-
year disease-free survival improved as the TRG increased, but 
this result was not statistically significant (P = 0.070, P = 0.125) 
(Fig. 2).
When comparing the TRG0-3 group and the TRG4 group, 
the three-year overall survival rates were 78% and 94%, and 
the three-year disease-free survival rates were 62% and 76%, 
respectively. The TRG4 group showed better OS and DFS rates 
and showed statistical significance in the three-year DFS (P = 
0.034) (Fig. 3). Also, 16 patients in the pathologic complete 
remission (pCR) group and the non-pCR group showed three-
year OS rates of 93% and 79%, and three-year DFS rates of 90% 
and 60%, respectively. The pCR group showed a better three-
year DFS rate than the non-pCR group, and this difference 
showed statistical significance (P = 0.025) (Fig. 4).
DISCUSSION
Preoperative chemoradiotherapy in locally advanced rectal 
cancer reduces local recurrence, increases operability, and in-
creases the anus conservation rate, ultimately increasing the 
survival rate. Heald et al. [14] introduced total mesorectal ex-
cision, and the local relapse rate was reduced to 7%, and the 
anal sphincter conservation rate was increased by more than 
20% [15]. From a Swedish rectal cancer trial, the group that 
underwent radiotherapy after surgery had an increased five-
year survival rate compared to the group that only had sur-
gery, 58% compared to 48% [16]. In other research after that, 
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Fig. 2. Cumulative three-year overall survival and three-year disease-free survival between groups according to tumor regression grade (TRG). 
A comparison of the two shows no statistically significant difference (P = 0.070, P = 0.125, Kaplan-Meier Life table analysis).
Table 6. Tumor recurrence and tumor regression grade (TRG)
TRG0 & 1 (n = 7) TRG2 (n = 17) TRG3 (n = 65) TRG4 (n = 19) Total (n = 108)
Local recurrence
a 3 (43) 4 (24)   9 (14) 0 (0) 16
Systemic recurrence
b 2 (29) 5 (29) 17 (26)   2 (11) 26
Both               2               1                6                0   9
Values are presented as number (%).
aP = 0.032; 
bP = 0.50.Journal of the Korean Society of
Coloproctology
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preoperative chemoradiotherapy increased the five-year sur-
vival rate to 68-91% and reduced local recurrence rate to 4- 
14% [17, 18].
There are reports that results for rectal cancer patients who 
had chemoradiotherapy before surgery are affected by prog-
nostic factors: tumor size before surgery, the response rate of 
the tumor, pathologic downstaging, surgical staging, and path-
ological findings. These factors are known to affect local tumor 
control and the survival rate [19-23]. Especially, pathological 
N stage is known to be the greatest factor affecting local tumor 
control and remote tumor control [13]. The downstaging rate 
caused by preoperative chemoradiotherapy is reported to be 
42-84% [24, 25]. In this study, 64 patients (60%) showed down-
staging and 26 patients (24%) showed N-stage reduction through 
CCRT.
Factors that can be used to determine the effects of preopera-
tive chemoradiotherapy are the pathologic downstaging, the 
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Fig. 4. Cumulative three-year overall survival and three-year disease-free survival (DFS) between the pathologic complete remission (pCR) 
group and the non-pCR group. The pCR group showed a better outcome. The three-year DFS in the pCR group showed statistical significance 
(P = 0.731, P = 0.025, Kaplan-Meier Life table analysis).
OS rate, the DFS rate, and resection margin and pathologic 
changing degree after CCRT. Although there are no general-
ized pathological standards, Dworak et al. [12] and Mandard 
et al. [7] categorizations are widely being used. In this research, 
Dworak’s categorization method was used to divide the tumors 
into five levels according to the fibrosis rate.
Janjan et al. [20] and Willet et al. [26] reported the preopera-
tive tumor size to be an important factor affecting the TRG. 
Das [27] insisted that the circumferential extent of the tumor, 
the tumor’s location with respect to the anal verge, and CEA 
results affected CCRT. In this research, however, we couldn’t 
measure tumor size before CCRT. The location of the tumor 
and the CEA did not affect the TRG, but perineural invasion 
and lymphovascular invasion were found to be a significant 
factors associated with TRG (P = 0.008, P = 0.032). 
Theodoropoulos [17] insisted that T stage reduction and com-
plete remission reduced relapse and increased the DFS. Garcia-
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Aguilar et al. [18] also said that complete remission reduced 
local relapse and increased the survival rate. From this research, 
as the TRG increased after CCRT, the OS and the DFS rates 
increased, and the local recurrence rate decreased (P = 0.032). 
As a result, the TRG is thought to have a local tumor suppres-
sion effect. Among the 89 patients in the TRG0-3 group, 66 
patients’ (74%) tumor samples were examined on circumfer-
ential resection margins (CRMs), and three patients of them 
had CRMs of less than 1 mm. In rectal cancer, the CRM is 
known to be an important prognostic factor twhat affects lo-
cal relapse and the survival rate [28-30]. However, local relapse 
was not found during follow-up observation in patients with 
a CRM less than 1 mm. The CRM was measured by reanalyz-
ing the slides, but we could not do this for every subject pa-
tients. More TRG, CRM, local recurrence, and survival research 
must be done in the future.
Habr-Gama et al. [10] insisted that rectal cancer in stage 0 
showed good OS and DFS rates and stage 0 with surgically 
treated group had more complications than observation only 
group. He insisted on follow-up observation in the clinically 
complete remission group. In this research, TRG4 and pCR 
patients showed better OS and DFS rates. The three-year OS 
rates of the TRG4 and the pCR groups were 76% and 90%, re-
spectively. The reason of survival difference between the two 
groups is that three patients from the TRG4 group were N (+), 
and one of them had lung metastasis.
Rodel et al. [13] reported that TRG could be a very important 
prognostic factor for rectal cancer. Suarez et al. [8] reported 
that the group with higher TRG showed a better DFS rate and 
that the TRG was a more significant prognostic factor than 
pathologic downstaging. However, the TRG cannot be con-
sidered as the only prognostic factor that affects rectal cancer 
patient’s survival rate after chemoradiotherapy; yT and yN are 
also thought to be crucial prognostic factors [31].
Preoperative chemoradiotherapy in rectal cancer reduces the 
local recurrence rate and increases the long-term survival rate 
by lowering pathologic tumor stage. The TRG, which shows 
the effect of chemoradiotherapy, is thought to be an additional 
prognostic factor that, along with TNM stage, affects the sur-
vival rate and the recurrence rate. Finally, standardization of 
the TRG system and more research on the factors that affect 
the TRG need to be done.
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